JP2020506180A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506180A5 JP2020506180A5 JP2019539974A JP2019539974A JP2020506180A5 JP 2020506180 A5 JP2020506180 A5 JP 2020506180A5 JP 2019539974 A JP2019539974 A JP 2019539974A JP 2019539974 A JP2019539974 A JP 2019539974A JP 2020506180 A5 JP2020506180 A5 JP 2020506180A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- dose
- composition according
- indapamide
- telmisartan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 22
- ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims 13
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 claims 12
- 229960004569 indapamide Drugs 0.000 claims 12
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 11
- 229960005187 telmisartan Drugs 0.000 claims 11
- 229960000528 amlodipine Drugs 0.000 claims 10
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 9
- 239000000480 calcium channel blocker Substances 0.000 claims 9
- 239000005458 thiazide-like diuretic Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 5
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 5
- 239000003087 receptor blocking agent Substances 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 3
- 229960004005 amlodipine besylate Drugs 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002934 diuretic Substances 0.000 claims 3
- -1 isladipine Chemical compound 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 230000001882 diuretic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229960003963 manidipine Drugs 0.000 claims 2
- ANEBWFXPVPTEET-UHFFFAOYSA-N manidipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ANEBWFXPVPTEET-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 238000011287 therapeutic dose Methods 0.000 claims 2
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 claims 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims 1
- 239000005485 Azilsartan Substances 0.000 claims 1
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims 1
- KJEBULYHNRNJTE-DHZHZOJOSA-N Cinalong Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC\C=C\C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 KJEBULYHNRNJTE-DHZHZOJOSA-N 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 claims 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims 1
- 229960002731 azilsartan Drugs 0.000 claims 1
- 229960002992 barnidipine Drugs 0.000 claims 1
- VXMOONUMYLCFJD-DHLKQENFSA-N barnidipine Chemical compound C1([C@@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@@H]2CN(CC=3C=CC=CC=3)CC2)=CC=CC([N+]([O-])=O)=C1 VXMOONUMYLCFJD-DHLKQENFSA-N 0.000 claims 1
- 229960000932 candesartan Drugs 0.000 claims 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims 1
- 229960003020 cilnidipine Drugs 0.000 claims 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
- 229960004166 diltiazem Drugs 0.000 claims 1
- APMMVXSVJLZZRR-UHFFFAOYSA-N diproteverine Chemical compound C1=C(OCC)C(OCC)=CC=C1CC1=NCCC2=CC(OC(C)C)=C(OC(C)C)C=C12 APMMVXSVJLZZRR-UHFFFAOYSA-N 0.000 claims 1
- 229950007849 diproteverine Drugs 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229960003580 felodipine Drugs 0.000 claims 1
- 229960002198 irbesartan Drugs 0.000 claims 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical group O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229960004773 losartan Drugs 0.000 claims 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 239000003607 modifier Substances 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229960000715 nimodipine Drugs 0.000 claims 1
- 229960000227 nisoldipine Drugs 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
- 229960001722 verapamil Drugs 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022199757A JP2023063282A (ja) | 2017-01-25 | 2022-12-14 | 高血圧症の処置のための組成物 |
| JP2024155192A JP2025010535A (ja) | 2017-01-25 | 2024-09-09 | 高血圧症の処置のための組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450324P | 2017-01-25 | 2017-01-25 | |
| US62/450,324 | 2017-01-25 | ||
| PCT/IB2018/000083 WO2018138578A1 (en) | 2017-01-25 | 2018-01-23 | Compositions for the treatment of hypertension |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199757A Division JP2023063282A (ja) | 2017-01-25 | 2022-12-14 | 高血圧症の処置のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506180A JP2020506180A (ja) | 2020-02-27 |
| JP2020506180A5 true JP2020506180A5 (enExample) | 2021-03-04 |
Family
ID=62979058
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539974A Pending JP2020506180A (ja) | 2017-01-25 | 2018-01-23 | 高血圧症の処置のための組成物 |
| JP2022199757A Pending JP2023063282A (ja) | 2017-01-25 | 2022-12-14 | 高血圧症の処置のための組成物 |
| JP2024155192A Pending JP2025010535A (ja) | 2017-01-25 | 2024-09-09 | 高血圧症の処置のための組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022199757A Pending JP2023063282A (ja) | 2017-01-25 | 2022-12-14 | 高血圧症の処置のための組成物 |
| JP2024155192A Pending JP2025010535A (ja) | 2017-01-25 | 2024-09-09 | 高血圧症の処置のための組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (6) | US10322117B2 (enExample) |
| EP (6) | EP4635566A2 (enExample) |
| JP (3) | JP2020506180A (enExample) |
| KR (4) | KR20250107955A (enExample) |
| CN (4) | CN120585831A (enExample) |
| AU (2) | AU2018213147B2 (enExample) |
| CA (1) | CA3051374A1 (enExample) |
| DK (2) | DK4101454T3 (enExample) |
| ES (2) | ES2940316T3 (enExample) |
| FI (2) | FI3573620T3 (enExample) |
| HR (2) | HRP20230267T1 (enExample) |
| HU (2) | HUE061444T2 (enExample) |
| LT (2) | LT3573620T (enExample) |
| MX (2) | MX2019008813A (enExample) |
| PL (2) | PL3573620T3 (enExample) |
| PT (2) | PT4101454T (enExample) |
| RS (2) | RS65701B1 (enExample) |
| RU (1) | RU2019126749A (enExample) |
| SI (2) | SI3573620T1 (enExample) |
| TW (5) | TWI825279B (enExample) |
| WO (1) | WO2018138578A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| AU2018213147B2 (en) | 2017-01-25 | 2023-08-31 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| JP2021536443A (ja) * | 2018-08-25 | 2021-12-27 | シーアールディー ファーマシューティカルズ インコーポレイティド | 高血圧治療をサーカディアンリズムと同期させる |
| CN111789843A (zh) * | 2019-04-08 | 2020-10-20 | 深圳奥萨医药有限公司 | 含氨氯地平、氯噻酮和阿米洛利的药物组合物 |
| CN113616651B (zh) * | 2020-05-08 | 2023-12-29 | 深圳奥萨制药有限公司 | 一种复方降压药物组合物及其应用 |
| US11730706B1 (en) * | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
| EP4574148A1 (en) | 2023-12-20 | 2025-06-25 | KRKA, d.d., Novo mesto | Fixed combination of telmisartan, amlodipine and indapamide for the treatment of hypertension |
| WO2025226012A1 (ko) | 2024-04-23 | 2025-10-30 | 신풍제약주식회사 | 칸데사르탄, 암로디핀 및 인다파미드를 포함하는 고혈압 예방 또는 치료용 약제학적 복합제제 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| EP1272220B2 (en) | 2000-04-10 | 2016-07-27 | Nicholas John Wald | Formulation for the prevention of cardiovascular disease |
| EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
| US20040198789A1 (en) * | 2003-02-28 | 2004-10-07 | Recordati Ireland Limited | Lercanidipine/ARB/diuretic therapeutic combinations |
| WO2005070462A2 (en) * | 2004-01-12 | 2005-08-04 | Sepracor, Inc. | Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use |
| EP1734958A1 (en) | 2004-04-06 | 2006-12-27 | Merck & Co., Inc. | Methods for the treatment of hypertension |
| KR100582347B1 (ko) | 2004-12-30 | 2006-05-22 | 한미약품 주식회사 | 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법 |
| US20070196510A1 (en) | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| EP2001469B1 (en) | 2006-03-16 | 2012-05-23 | Metabolic Solutions Development Company LLC | Thiazolidinedione analogues |
| WO2007146900A2 (en) | 2006-06-15 | 2007-12-21 | Gilead Colorado, Inc. | Antihypertensive therapy method |
| CA2697057A1 (en) | 2007-08-22 | 2009-02-26 | Gilead Colorado, Inc. | Therapy for complications of diabetes |
| KR20090057538A (ko) * | 2007-12-03 | 2009-06-08 | 박사룡 | 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물 |
| CN101450211A (zh) * | 2007-12-07 | 2009-06-10 | 上海艾力斯医药科技有限公司 | 复方降压制剂 |
| DE102008059206A1 (de) | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN101966187A (zh) * | 2009-07-14 | 2011-02-09 | 邬林祥 | 一种治疗高血压含氨氯地平和厄贝沙坦的复方制剂 |
| CN101618215A (zh) | 2009-08-16 | 2010-01-06 | 王丽燕 | 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物 |
| MY161853A (en) | 2010-05-03 | 2017-05-15 | Tsh Biopharm Corp Ltd | Pharmaceutical composition and method for treating hypertension |
| WO2011149438A1 (en) * | 2010-05-28 | 2011-12-01 | Mahmut Bilgic | Combination of antihypertensive agents |
| CN101966190A (zh) * | 2010-07-17 | 2011-02-09 | 邬林祥 | 一种治疗高血压含氨氯地平和依普罗沙坦的复方制剂 |
| CN102225203A (zh) * | 2011-06-29 | 2011-10-26 | 北京阜康仁生物制药科技有限公司 | 一种用于降低血压的药用组合物 |
| CN102327272B (zh) | 2011-07-14 | 2013-08-14 | 海南锦瑞制药股份有限公司 | 一种口服固体药用组合物及其制备方法 |
| US10918612B2 (en) * | 2013-01-22 | 2021-02-16 | Markus Zwickl | Combinations with 2-aminoethanesulfonic acid |
| US9839644B2 (en) * | 2014-09-09 | 2017-12-12 | ARKAY Therapeutics, LLC | Formulations and methods for treatment of metabolic syndrome |
| CZ2015687A3 (cs) | 2015-10-02 | 2017-04-12 | Zentiva, K.S. | Farmaceutická kompozice obsahující kombinaci kandesartanu, amlodipinu a hydrochlorthiazidu |
| CN106074418A (zh) | 2016-06-23 | 2016-11-09 | 南京华宽信息咨询中心 | 一种治疗高血压的苯磺酸氨氯地平片及其制备方法 |
| CN106310278A (zh) * | 2016-08-01 | 2017-01-11 | 深圳奥萨制药有限公司 | 一种含叶酸的多联降压药物组合物 |
| US10369156B2 (en) | 2016-11-15 | 2019-08-06 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| AU2018213147B2 (en) | 2017-01-25 | 2023-08-31 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| US20250205210A1 (en) | 2017-01-25 | 2025-06-26 | The George Institute for Global Health | Compositions for the treatment of hypertension |
| BR112021001374A2 (pt) | 2018-07-26 | 2021-07-06 | The George Inst For Global Health | composições para o tratamento da hipertensão |
-
2018
- 2018-01-23 AU AU2018213147A patent/AU2018213147B2/en active Active
- 2018-01-23 PL PL18745362.6T patent/PL3573620T3/pl unknown
- 2018-01-23 CN CN202510891838.2A patent/CN120585831A/zh active Pending
- 2018-01-23 HU HUE18745362A patent/HUE061444T2/hu unknown
- 2018-01-23 LT LTEPPCT/IB2018/000083T patent/LT3573620T/lt unknown
- 2018-01-23 EP EP25191988.2A patent/EP4635566A2/en active Pending
- 2018-01-23 WO PCT/IB2018/000083 patent/WO2018138578A1/en not_active Ceased
- 2018-01-23 HU HUE22188172A patent/HUE067617T2/hu unknown
- 2018-01-23 DK DK22188172.5T patent/DK4101454T3/da active
- 2018-01-23 CN CN202310463571.8A patent/CN116327958A/zh active Pending
- 2018-01-23 RS RS20240644A patent/RS65701B1/sr unknown
- 2018-01-23 ES ES18745362T patent/ES2940316T3/es active Active
- 2018-01-23 LT LTEP22188172.5T patent/LT4101454T/lt unknown
- 2018-01-23 SI SI201830873T patent/SI3573620T1/sl unknown
- 2018-01-23 PT PT221881725T patent/PT4101454T/pt unknown
- 2018-01-23 EP EP25186476.5A patent/EP4620524A3/en active Pending
- 2018-01-23 CN CN202411603186.XA patent/CN119386015A/zh active Pending
- 2018-01-23 FI FIEP18745362.6T patent/FI3573620T3/fi active
- 2018-01-23 RU RU2019126749A patent/RU2019126749A/ru unknown
- 2018-01-23 EP EP25190561.8A patent/EP4609913A3/en active Pending
- 2018-01-23 HR HRP20230267TT patent/HRP20230267T1/hr unknown
- 2018-01-23 PT PT187453626T patent/PT3573620T/pt unknown
- 2018-01-23 DK DK18745362.6T patent/DK3573620T3/da active
- 2018-01-23 MX MX2019008813A patent/MX2019008813A/es unknown
- 2018-01-23 KR KR1020257021924A patent/KR20250107955A/ko active Pending
- 2018-01-23 EP EP22188172.5A patent/EP4101454B1/en active Active
- 2018-01-23 PL PL22188172.5T patent/PL4101454T3/pl unknown
- 2018-01-23 EP EP18745362.6A patent/EP3573620B1/en active Active
- 2018-01-23 SI SI201831107T patent/SI4101454T1/sl unknown
- 2018-01-23 HR HRP20240701TT patent/HRP20240701T1/hr unknown
- 2018-01-23 KR KR1020257011127A patent/KR20250052479A/ko active Pending
- 2018-01-23 EP EP24164449.1A patent/EP4374915A3/en active Pending
- 2018-01-23 RS RS20230204A patent/RS64042B1/sr unknown
- 2018-01-23 CN CN201880021071.6A patent/CN110545819A/zh active Pending
- 2018-01-23 ES ES22188172T patent/ES2981657T3/es active Active
- 2018-01-23 FI FIEP22188172.5T patent/FI4101454T3/fi active
- 2018-01-23 CA CA3051374A patent/CA3051374A1/en active Pending
- 2018-01-23 JP JP2019539974A patent/JP2020506180A/ja active Pending
- 2018-01-23 KR KR1020247019312A patent/KR20240096848A/ko not_active Ceased
- 2018-01-23 KR KR1020197024682A patent/KR20190127691A/ko not_active Ceased
- 2018-01-25 TW TW109105655A patent/TWI825279B/zh active
- 2018-01-25 TW TW107102631A patent/TW201831204A/zh unknown
- 2018-01-25 TW TW112101171A patent/TWI852279B/zh active
- 2018-01-25 TW TW113126576A patent/TW202508572A/zh unknown
- 2018-01-25 TW TW112142923A patent/TW202421198A/zh unknown
- 2018-03-13 US US15/919,923 patent/US10322117B2/en active Active
-
2019
- 2019-04-24 US US16/393,774 patent/US10799487B2/en active Active
- 2019-07-24 MX MX2023004366A patent/MX2023004366A/es unknown
-
2020
- 2020-09-08 US US17/014,358 patent/US11478462B2/en active Active
-
2022
- 2022-09-16 US US17/932,982 patent/US12102623B2/en active Active
- 2022-12-14 JP JP2022199757A patent/JP2023063282A/ja active Pending
-
2023
- 2023-08-08 US US18/446,268 patent/US12285415B2/en active Active
- 2023-11-27 AU AU2023274064A patent/AU2023274064A1/en active Pending
-
2024
- 2024-09-09 JP JP2024155192A patent/JP2025010535A/ja active Pending
-
2025
- 2025-04-01 US US19/097,314 patent/US12465599B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506180A5 (enExample) | ||
| RU2019126749A (ru) | Композиции для лечения гипертензии | |
| CA2514921A1 (en) | Combined use of olmesartan medoxomil and azelnidipine or amlodipine for the treatment of arteriosclerosis and hypertension | |
| CA2613417A1 (en) | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker | |
| KR102700778B1 (ko) | 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물 | |
| JP2010507602A5 (enExample) | ||
| RU2014111474A (ru) | Способы лечения сердечно-сосудистых нарушений | |
| JP2019536816A5 (enExample) | ||
| PE20040439A1 (es) | Combinacion de compuestos organicos | |
| HUP0102828A2 (hu) | Valzartant és kalciumcsatorna blokkolót tartalmazó vérnyomáscsökkentő kombináció és alkalmazása | |
| JP2020508339A5 (enExample) | ||
| JP2005533023A5 (enExample) | ||
| AR055630A1 (es) | Derivados de diazaspiro como antagonistas del receptor ccr8, un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades respiratorias. | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| JP2014531461A5 (enExample) | ||
| KR20090057538A (ko) | 안지오텐신 투 안타고니스트, 칼슘 안타고니스트 및이뇨제를 함유하는 고혈압 치료제 조성물 | |
| JP2020536919A5 (enExample) | ||
| PE20110844A1 (es) | Composicion farmaceutica solida | |
| BRPI0706863A2 (pt) | composição de fármacos, uso de uma composição de fármacos e embalagem comercial | |
| MA39163B1 (fr) | Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine | |
| JP6532984B2 (ja) | 高血圧症の予防又は治療のための併用医薬 | |
| Hamaguchi et al. | Addressing phototoxicity observed in a novel series of biaryl derivatives: Discovery of potent, selective and orally active phosphodiesterase 10A inhibitor ASP9436 | |
| JP2018521077A5 (enExample) | ||
| RU2023129881A (ru) | Композиции для лечения гипертензии | |
| JP6934859B2 (ja) | 腎疾患の治療のための医薬 |